• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Movano Inc.

    1/7/26 11:20:15 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001603704
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Movano Inc.
    SEC File Number
    001-40254
    Address of Issuer
    6800 Koll Center Parkway
    Pleasanton
    CALIFORNIA
    94566
    Phone
    415-651-3172
    Name of Person for Whose Account the Securities are To Be Sold
    Michael Leabman
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director and CTO

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common Stock
    J.P. Morgan Securities LLC
    270 Park Ave
    10th Floor
    New York � NY � 10017
    2100015000083485701/07/2026
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/03/2025Cashless Option Exercise and SaleMovano Inc (issuer)Checkbox not checked4225001/08/2026cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/07/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    J.P. Morgan Securities LLC, Workplace Solutions, as Agent and Attorney in Fact for Michael Leabman, Movano Inc

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvex Secures Long-Term NVIDIA H200 GPU Deployment with AI-driven Provider of High-Performance Battery Technologies to Support Production AI Workloads

    Filed by Movano Inc.pursuant to Rule 425 under the Securities Act of 1933and deemed filed pursuant to Rule 14a-12under the Securities Exchange Act of 1934Subject Company: Movano Inc.Commission File No.: 001-40254Date: January 22, 2026 ARLINGTON, Va., Jan. 22, 2026 /PRNewswire/ -- Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure for AI workloads, today announced a long-term GPU lease agreement with an established AI-driven provider of high-performance battery technologies. The deployment, a dedicated cluster of NVIDIA H200 GPUs, will underpin the customer's core AI development and research initiatives, including proprietary algorithms. The customer s

    1/22/26 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Announces Reverse Stock Split

    Shares Expected to Begin Trading on Split-Adjusted Basis on October 10, 2025 PLEASANTON, Calif., Oct. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on October 10, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Friday, October 10, 2025, and will continue to trade on The Nasdaq Capital Market under the symbol "MOVE." The new CUSIP number for the common stock will be 62459M 305.

    10/8/25 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Granted Listing Extension by Nasdaq

    PLEASANTON, Calif., Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that, by letter received on August 27, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to (i) the Company regaining compliance with Listing Rule 5250(c)(1), requiring the timely filing of periodic reports (the "Period Filing Rule"), by filing its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 on or before September 30, 2025, and (ii) the Company demonstrating compliance with Listing Rule 5550(a)(2), requiring the main

    8/28/25 4:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mastrototaro John exercised 72,834 shares at a strike of $1.25 and sold $687,949 worth of shares (33,069 units at $20.80), increasing direct ownership by 243% to 56,114 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    1/28/26 5:16:47 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Cogan Jeremy sold $597,258 worth of shares (28,736 units at $20.78) and exercised 64,834 shares at a strike of $1.25, increasing direct ownership by 148% to 60,504 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    1/28/26 5:15:46 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Leabman Michael Aaron was granted 11,174 shares, increasing direct ownership by 49% to 33,813 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    1/22/26 5:32:36 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Movano Inc.

    S-1/A - Movano Inc. (0001734750) (Filer)

    2/9/26 5:00:29 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form S-4/A filed by Movano Inc.

    S-4/A - Movano Inc. (0001734750) (Filer)

    2/4/26 9:56:54 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 425 filed by Movano Inc.

    425 - Movano Inc. (0001734750) (Subject)

    1/22/26 7:08:16 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Financials

    Live finance-specific insights

    View All

    Movano Health Reports Q3 2024 Financial Results and Provides Business Update

    Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

    11/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Reports Q2 2024 Financial Results and Provides Business Update

    Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

    8/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Provides Progress Update on EvieMED Regulatory Filing

    Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

    8/5/24 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care